Approval Of Servier’s Voranigo For Certain Brain Tumors Validates Oncology Strategy

 
• By Jessica Merrill

The drug prolonged progression-free survival by 16.6 months in Phase III. Chief commercial officer Arjun Prasad talked about the company’s launch plans in an interview.

Servier's Voranigo was approved by FDA • Source: Shutterstock

More from New Products

More from Scrip